Vascular endothelial growth factor α (VEGFα) is a well-established biomarker in meningiomas and can be selectively targeted by bevacizumab conjugated to the IRDye800CW, forming the tracer bevacizumab-IRDye800CW [99,100]. The gene discussed is VEGFA; the disease is meningioma.